Sugi Predict

Sugi Predict / Compounds / SCHEMBL1728343

SCHEMBL1728343

SCHEMBL1728343

O=C(O[CH]c1ccccc1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.54
▸ F2 P00734 1/20 0.54
▸ PLA2G7 Q13093 2/20 0.53
▸ TSHR P16473 4/20 0.50
▸ MAPT P10636 4/20 0.45
▸ TDP1 Q9NUW8 3/20 0.45
▸ TP53 P04637 1/20 0.45
▸ AKR1C1 Q04828 1/20 0.45
▸ PLIN1 O60240 1/20 0.45
▸ BCHE P06276 1/20 0.45
▸ TNFRSF1A P19438 1/20 0.45
▸ ACHE P22303 1/20 0.45
▸ MAOB P27338 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ PLIN5 Q00G26 1/20 0.45
▸ CYP1B1 Q16678 1/20 0.45
▸ ABHD5 Q8WTS1 1/20 0.45
▸ KMT2A Q03164 4/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2900886 0.82 CYP1A1 (0.56) LMNAMAPTTDP1CYP1B1KMT2A
SCHEMBL28182671 0.79 LMNA (0.61) LMNAF2PLA2G7TSHRMAPT
SCHEMBL11229507 0.79 LMNA (0.61) LMNAF2PLA2G7TSHRMAPT
SCHEMBL10455847 0.79 PLA2G7 (0.53) LMNAF2PLA2G7TSHRMAPT
SCHEMBL385227 0.79 PLA2G7 (0.53) LMNAF2PLA2G7TSHRMAPT
SCHEMBL229640 0.77 LMNA (0.58) LMNAF2PLA2G7TSHRMAPT
Benzene SCHEMBL28103328 0.77 LMNA (0.58) LMNAF2PLA2G7TSHRMAPT
SCHEMBL9215281 0.76 LMNA (0.56) LMNAF2PLA2G7TSHRMAPT
SCHEMBL8422588 0.76 LMNA (0.56) LMNAF2PLA2G7TSHRMAPT
SCHEMBL7773659 0.76 LMNA (0.56) LMNAF2PLA2G7TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114716386-A Novel exosome inhibitor and preparation method thereof 北京和理咨询有限公司 2022-07-08 — — CN claimed
CN-107847607-A Aptamer conjugate of paclitaxel or derivative thereof, and preparation method and application thereof 北京和理咨询有限公司 2018-03-27 — — CN claimed
US-9809822-B2 Triptolide derivatives and preparation method and use thereof HONG KONG BAPTIST UNIVERSITY (HK) 2017-11-07 — — US claimed
CN-105121455-B Novel triptolide derivative and preparation method and application thereof 香港浸会大学 2017-06-16 — — CN claimed
US-20160362691-A1 TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF HONG KONG BAPTIST UNIVERSITY (HK) 2016-12-15 — — US claimed
CN-105121455-A Novel triptolide derivative and preparation method and application thereof UNIV HONG KONG BAPTIST 2015-12-02 — — CN claimed
EP-0513016-A1 CYCLOALKYL-SUBSTITUTED GLUTARAMIDE DIURETIC AGENTS Pfizer Limited (GB) 1992-11-19 — — EP claimed
EP-0342850-B1 ENANTIOMERIC GLUTARAMIDE DIURETIC AGENTS Pfizer Limited (GB) 1992-05-20 — — EP claimed
CN-1015361-B ENANTIOMERIC GLUTARAMIDE DIURETIC AGENTS PFIZER (US) 1992-02-05 — — CN claimed
EP-0274234-B1 SPIRO-SUBSITUTED GLUTARAMIDE DIURETIC AGENTS Pfizer Limited (GB) 1991-09-11 — — EP claimed
US-5030654-A Glutaramide diuretic agents PFIZER INC. (US) 1991-07-09 — — US claimed
CN-1037704-A The glutaramide diuretic agents of enantiomorph PFIZER (US) 1989-12-06 — — CN claimed
EP-0342850-A1 Enantiomeric glutaramide diuretic agents Pfizer Limited (GB) 1989-11-23 — — EP claimed
EP-0274234-A2 Spiro-subsituted glutaramide diuretic agents Pfizer Limited (GB) 1988-07-13 — — EP claimed
CN-116622005-A Polymer prodrug compound and preparation method thereof, and polymer prodrug micelle and preparation method thereof 成都普康生物科技有限公司 2023-08-22 — — CN disclosed
CN-114716386-A Novel exosome inhibitor and preparation method thereof 北京和理咨询有限公司 2022-07-08 — — CN disclosed
CN-107847607-B Aptamer conjugate of paclitaxel or derivative thereof, and preparation method and application thereof 北京盈科瑞创新医药股份有限公司 2020-11-20 — — CN disclosed
US-4443435-A ANTICARCINOGENS, HYPOTENSIVE AGENTS, HYPERTHYROIDISM MERCK & CO., INC. (US) 1984-04-17 — — US disclosed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 — — EP disclosed
EP-0038541-A1 Novel prodrugs of biologically active agents containing mercapto groups, process for preparing and therapeutically effective composition containing the same MERCK & CO. INC. (US) 1981-10-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362691-A1 TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF TPD52L2, TRDMT1, MCTS1 LMNA 91/4885F2 2649/4885PLA2G7 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.